21 related articles for article (PubMed ID: 23932896)
1. Inflammation and Neurodegeneration in Glaucoma: Isolated Eye Disease or a Part of a Systemic Disorder? - Serum Proteomic Analysis.
Okruszko MA; Szabłowski M; Zarzecki M; Michnowska-Kobylińska M; Lisowski Ł; Łapińska M; Stachurska Z; Szpakowicz A; Kamiński KA; Konopińska J
J Inflamm Res; 2024; 17():1021-1037. PubMed ID: 38370463
[TBL] [Abstract][Full Text] [Related]
2. Insight into the divergent role of TRAIL in non-neoplastic neurological diseases.
Gao S; Fang Y; Tu S; Chen H; Shao A
J Cell Mol Med; 2020 Oct; 24(19):11070-11083. PubMed ID: 32827246
[TBL] [Abstract][Full Text] [Related]
3. Adrenocorticotropic hormone
Berkovich R; Bakshi R; Amezcua L; Axtell RC; Cen SY; Tauhid S; Neema M; Steinman L
Ther Adv Neurol Disord; 2017 Jan; 10(1):3-17. PubMed ID: 28450891
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives of TRAIL: insights into central nervous system disorders.
Tisato V; Gonelli A; Voltan R; Secchiero P; Zauli G
Cell Mol Life Sci; 2016 May; 73(10):2017-27. PubMed ID: 26910728
[TBL] [Abstract][Full Text] [Related]
5. Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.
Borràs E; Cantó E; Choi M; Maria Villar L; Álvarez-Cermeño JC; Chiva C; Montalban X; Vitek O; Comabella M; Sabidó E
Mol Cell Proteomics; 2016 Jan; 15(1):318-28. PubMed ID: 26552840
[TBL] [Abstract][Full Text] [Related]
6. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
7. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
Pelli N; Floreani A; Torre F; Delfino A; Baragiotta A; Contini P; Basso M; Picciotto A
Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis.
Moreno M; Sáenz-Cuesta M; Castilló J; Cantó E; Negrotto L; Vidal-Jordana A; Montalban X; Comabella M
J Neuroimmunol; 2013 Oct; 263(1-2):152-4. PubMed ID: 23932896
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in multiple sclerosis.
Zipp F
Cell Tissue Res; 2000 Jul; 301(1):163-71. PubMed ID: 10928289
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
